α-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles

Colloids and Surfaces B: Biointerfaces

Volumn 140, Issue , 2016, Pages 246-253

  Oliveira, Mariana S ^a   Mussi, Samuel V ^a   Gomes, Dawidson A ^a   Yoshida, Maria Irene ^a   Frezard, Frederic ^a   Carregal, Virgínia M ^a   Ferreira, Lucas A M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Cancer; Cytotoxicity; Doxorubicin; Solid lipid nanoparticle; Tocopherol succinate

Indexed keywords

CYTOTOXICITY; DISEASES; DRUG PRODUCTS; EFFICIENCY; NANOPARTICLES; PARTICLE SIZE;

ANTICANCER ACTIVITIES; BREAST CANCER CELLS; CANCER; CONTROLLED DRUG RELEASE; DOXORUBICIN; DRUG ENCAPSULATION EFFICIENCY; ENTRAPMENT EFFICIENCY; SOLID LIPID NANOPARTICLE (SLN);

ENCAPSULATION;

ALPHA TOCOPHEROL SUCCINATE; DOXORUBICIN; SOLID LIPID NANOPARTICLE; ALPHA TOCOPHEROL; ANTINEOPLASTIC ANTIBIOTIC; LIPID; NANOPARTICLE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RELEASE; ENCAPSULATION; ENTRAPMENT EFFICIENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL PARAMETERS; PRIORITY JOURNAL; THERMAL ANALYSIS; ZETA POTENTIAL; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFECTS; DRUG FORMULATION; MCF-7 CELL LINE; TUMOR CELL LINE;

ALPHA-TOCOPHEROL; ANTIBIOTICS, ANTINEOPLASTIC; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG COMPOUNDING; DRUG LIBERATION; HUMANS; LIPIDS; MCF-7 CELLS; MOLECULAR STRUCTURE; NANOPARTICLES; PARTICLE SIZE;

EID: 84953750862     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.12.019     Document Type: Article

References (36)

1. Carvalho C., Santos R.X., Cardoso S., Correia S., Oliveira P.J., Santos Moreira M.S. Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem. 2009, 16:3267-3285.
2. Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 2013, 65:157-170.
3. Lipshultz S.E., Cochran T.R., Franco V.I., Miller T.L. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat. Rev. Clin. Oncol. 2013, 10:697-710.
4. Vyas D., Laput G., Vyas A.K. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. OncoTargets Ther. 2014, 7:1015-1023.
5. Volkova M., Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr. Cardiol. Rev. 2011, 4:214-220.
6. Sawyer D.B., Peng X., Chen B., Pentassuglia L., Lim C.C. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection. Prog. Cardiovasc. Dis. 2010, 53:105-113.
7. Shylasree T.S., Bryant A., Athavale R. Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. Cochrane Database Syst. Rev. 2013, 2:1-17.
8. Livi L., Meattini I., Cardillo C.D.L., Mangoni M., Greto D., Petrucci A., Rampini A., Bruni A., Galardi A., Cataliotti L., Biti G. Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis. Tumori 2009, 95:422-426.
9. Jassem J., Pieńkowski T., Płuzańska A., Jelic S., Gorbunova V., Mrsic-Krmpotic Z., Berzins J., Nagykalnai T., Wigler N., Renard J., Munier S., Weil C. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J. Clin. Oncol. 2001, 19:1707-1715.
10. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011, 63:131-135.
11. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
12. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
13. Wissing S.A., Kayserb O., Müller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
14. Serpe L., Catalanob M.G., Cavallic R., Ugazioc E., Boscob O., Canaparoa R., Muntoni E., Frairia R., Gasco M.R., Eandi M., Zara G.P. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm. 2004, 58:673-680.
15. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 2004, 93:1993-2008.
16. Wong H.L., Rauth A.M., Bendayan R., Manias J.L., Ramaswamy M., Liu Z., Erhan S.Z., Wu X.Y. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res. 2006, 23:1574-1585.
17. Fundarò A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Gasco M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 2000, 42:337-343.
18. Mussi S.V., Silva R.C., Oliveira M.C., Lucci C.M., Azevedo R.B., Ferreira L.A.M. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur. J. Pharm. Sci. 2013, 48:282-290.
19. Prasad K.N., Kumar B., Yan X.D., Hanson A.J., Cole W.C. Alpha tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J. Am. Coll. Nutr. 2003, 22:108-117.
20. Malafa M.P., Neitzel L.T. Vitamin E succinate promotes breast cancer tumor dormancy. J. Surg. Res. 2000, 93:163-170.
21. Kanai K., Kikuchi E., Mikami S., Suzuki E., Uchida Y., Kodaira K., Miyajima A., Ohigashi T., Nakashima J., Oya M. Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo. Cancer Sci. 2010, 101:216-223.
22. Malafa M.P., Fokum F.D., Andoh J., Neitzel L.T., Bandyopadhyay S., Zhan R., Iiizumi M., Furuta E., Horvath E., Watabe K. Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis. Int. J. Cancer 2006, 118:2441-2447.
23. Gu X., Song X., Dong Y., Cai H., Walters E., Zhang R., Pang X., Xie T., Guo Y., Sridhar R., Califano J.A. Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo. Clin. Cancer Res. 2008, 14:1840-1848.
24. Zhang X., Peng X., Yu W., Hou S., Zhao Y., Zhang Z., Huang X., Wu K. α-Tocopheryl succinate enhances doxorubicin-induced apoptosis in human gastric cancer cells via promotion of doxorubicin influx and suppression of doxorubicin efflux. Cancer Lett. 2011, 307:174-181.
25. Alvarez-Cedrón L., Sayalero M.L., Lanao J.M. High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. J. Chromatogr. B 1999, 721:271-278.
26. Wong H.L., Rauth A.M., Bendayan R., Wu X.Y. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur. J. Pharm. Biopharm. 2007, 65:300-308.
27. Bunjes H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J. Pharm. Pharmacol. 2010, 62:1637-1645.
28. Rosenblatt K.M., Douroumis D., Bunjes H. Drug release from differently structured monoolein/poloxamer nanodispersions studied with differential pulse polarography and ultrafiltration at low pressure. J. Pharm. Sci. 2007, 96:1564-1575.
29. Shalviri A., Raval G., Prasad P., Chan C., Liu Q., Heerklotz H., Rauth A.M., Wu X.Y. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells. Eur. J. Pharm. Biopharm. 2012, 82:587-597.
30. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
31. Seidlitz A., Weitschies W. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing. J. Pharm. Pharmacol. 2012, 64:969-985.
32. Ma P., Dong X., Swadley C.L., Gupte A., Leggas M., Ledebur H.C., Mumper R.J. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in Leukemia. J. Biomed. Nanotechnol. 2009, 5:151-161.
33. Mussi S.V., Sawant R., Perche F., Oliveira M.C., Azevedo R.B., Ferreira L.A.M., Torchilin V.P. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells. Pharm. Res. 2014, 31:1882-1892.
34. Shuhendler A.J., Cheung R.Y., Manias J., Connor A., Rauth A.M., Wu X.Y. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat. 2010, 2:255-269.
35. Siddiqui A., Gupta V., Liu Y.Y., Nazzal S. Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES). Int. J. Pharm. 2012, 431:222-229.
36. Roby M.H., De Castro V.C., Targino B.N., Alves Da Silva P.H., Mangavel C., Chretien F., Humeau C., Desobry S. Oxidative stability of DHA phenolic ester. Food Chem. 2015, 169:41-48.